The use of NNMT inhibitors as a potential obesity treatment has been investigated preclinically8,9,13, and observational clinical data suggests that increased NNMT expression and activity correlate with increased incidence of Type 2 diabetes (T2D) and risk of obesity, respectively10,11. The gene discussed is NNMT; the disease is obesity due to melanocortin 4 receptor deficiency.